Abnormal dreams · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to higher abnormal dreams compared with doxycycline; GRADE not reported.
1 finding from 1 review
Insomnia · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to higher insomnia compared with doxycycline; GRADE not reported.
1 finding from 1 review
Anxiety · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to higher anxiety compared with doxycycline; GRADE not reported.
1 finding from 1 review
Depressed mood · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to higher depressed mood compared with doxycycline; GRADE not reported.
1 finding from 1 review
Abnormal thoughts or perceptions · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine showed no clear difference in abnormal thoughts or perceptions compared with doxycycline; GRADE not reported.
1 finding from 1 review
Nausea · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to lower nausea compared with doxycycline; GRADE not reported.
1 finding from 1 review
Vomiting · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to lower vomiting compared with doxycycline; GRADE not reported.
1 finding from 1 review
Abdominal pain · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine showed no clear difference in abdominal pain compared with doxycycline; GRADE not reported.
1 finding from 1 review
Diarrhoea · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to lower diarrhoea compared with doxycycline; GRADE not reported.
1 finding from 1 review
Discontinuation of medication due to adverse events · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher discontinuation of drug due to adverse effects compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Dyspepsia · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to lower dyspepsia compared with doxycycline; GRADE not reported.
1 finding from 1 review
Headache · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine showed no clear difference in headache compared with doxycycline; GRADE not reported.
1 finding from 1 review
Dizziness · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine showed no clear difference in dizziness compared with doxycycline; GRADE not reported.
1 finding from 1 review
Visual impairment · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to higher visual impairment compared with doxycycline; GRADE not reported.
1 finding from 1 review
Pruritis · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to lower pruritis compared with doxycycline; GRADE not reported.
1 finding from 1 review
Photosensitivity · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to lower photosensitivity compared with doxycycline; GRADE not reported.
1 finding from 1 review
Vaginal thrush · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to lower vaginal thrush compared with doxycycline; GRADE not reported.
1 finding from 1 review
Abnormal dreams · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher abnormal dreams compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Insomnia · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher insomnia compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Anxiety · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher anxiety compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review